Crossbow Therapeutics Fuels T-Cell Engager Pipeline with $77 Million Series B
March 22, 2026, 3:55 am
Crossbow Therapeutics secured $77 million in Series B funding to propel its innovative TCR-mimetic antibody cancer therapies. This substantial capital injection will accelerate the development of critical T-cell engager programs. Funds will advance lead candidate CBX-250 through its ongoing Phase 1 trial for myeloid malignancies, with data expected by late 2026. The investment also supports CBX-663, a next-generation T-cell engager targeting both hematologic and solid tumors, slated for Phase 1 in Q3 2026. Crossbow’s unique T-Bolt platform broadens immunotherapy's scope. It targets previously inaccessible intracellular cancer proteins. Co-led by Taiho Ventures and Arkin Bio Capital, this financing underscores strong investor confidence in Crossbow's potential to redefine cancer treatment paradigms.
Cambridge-based Crossbow Therapeutics has announced a significant financial milestone. The biotechnology firm raised $77 million in Series B funding. This capital infusion will accelerate development of its groundbreaking cancer therapies. The focus remains on a broad range of malignancies.
The Series B round saw strong participation. Taiho Ventures and Arkin Bio Capital co-led the financing. Several new investors joined the effort. These included Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, and Blood Cancer United’s Therapy Acceleration Program. Existing investors also reaffirmed their commitment. MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, and Mirae Asset Venture Investment all participated.
This substantial funding round empowers Crossbow Therapeutics. The company aims to advance its T-cell engager (TCE) programs. These programs utilize a novel approach to target cancer cells. They promise expanded treatment options for patients. The investment signals strong confidence in Crossbow’s innovative pipeline.
Crossbow's core technology involves TCR-mimetic antibodies. These antibodies mimic T-cell receptors. This unique design allows them to target intracellular cancer proteins. Such proteins have historically proven difficult to reach. Conventional antibody therapies often fail to access these targets. Crossbow's method breaks this barrier.
The company's T-Bolt platform is central to its strategy. This platform develops a portfolio of T-cell engager therapies. T-Bolt molecules precisely bind to peptide human leukocyte antigen (pHLA) complexes on cancer cells. This mechanism directs the body’s immune system to destroy malignant cells. The platform aims to expand immunotherapy’s reach. It targets a wide spectrum of cancers, offering new hope.
A primary use of the new capital is to push CBX-250 forward. CBX-250 is Crossbow’s lead candidate. It represents a first-in-class T-cell engager. The therapy targets specific pHLA on myeloid cancer cells. This specificity is crucial for effective treatment.
CBX-250 is currently undergoing a Phase 1 clinical trial. The study is named CROSSCHECK-001. It evaluates the therapy in patients with relapsed or refractory myeloid malignancies. These severe conditions include acute myeloid leukemia. Chronic myeloid leukemia also falls within its scope. Myelodysplastic syndromes and chronic myelomonocytic leukemia are other target indications. Initial clinical data from this trial is eagerly anticipated. The company expects results by the end of 2026. This data will be critical for future development.
The financing also supports the advancement of CBX-663. This is another promising first-in-class T-cell engager. CBX-663 targets a telomerase reverse transcriptase-derived peptide HLA complex. This broadens its potential application. It represents the next wave in Crossbow’s pipeline innovation.
Crossbow Therapeutics plans to submit an Investigational New Drug (IND) application for CBX-663 soon. A Phase 1 clinical trial is slated for the third quarter of 2026. This therapy will target both hematologic and solid tumors. Its broader applicability could address a significant unmet need.
Strategic leadership changes accompany the funding. Sakae Asanuma has joined Crossbow’s board of directors. Asanuma serves as President and CEO of Taiho Ventures. Pini Orbach also joined the board. Orbach is Managing Partner of Arkin Bio Capital. Their expertise will guide Crossbow’s future direction.
Crossbow’s approach is designed to overcome limitations of current treatments. The T-Bolt platform potentially targets the entire universe of cancer proteins. This expansive capability promises to deliver impact for patients. It aims to address cancers previously considered untreatable with antibody therapies.
The company will share new insights soon. Preclinical and translational data on both CBX-250 and CBX-663 will be presented. The American Association for Cancer Research (AACR) 2026 Annual Meeting in April will host these presentations. This will offer the scientific community an early look at Crossbow’s progress.
Crossbow Therapeutics is expanding its operations. Research and development efforts will intensify. The focus remains on broadening the scope of immunotherapy. The ultimate goal is to provide next-generation TCR-mimetic immunotherapies. Patients facing limited options urgently need these innovations. This funding fuels that critical mission.
The $77 million investment underscores a shared conviction. Investors believe in the transformative potential of the T-Bolt platform. This commitment empowers Crossbow to efficiently expand its pipeline. The company aims to address cancers beyond the reach of today’s existing therapies. It represents a vital step forward in the fight against cancer.
Cambridge-based Crossbow Therapeutics has announced a significant financial milestone. The biotechnology firm raised $77 million in Series B funding. This capital infusion will accelerate development of its groundbreaking cancer therapies. The focus remains on a broad range of malignancies.
The Series B round saw strong participation. Taiho Ventures and Arkin Bio Capital co-led the financing. Several new investors joined the effort. These included Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, and Blood Cancer United’s Therapy Acceleration Program. Existing investors also reaffirmed their commitment. MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, and Mirae Asset Venture Investment all participated.
This substantial funding round empowers Crossbow Therapeutics. The company aims to advance its T-cell engager (TCE) programs. These programs utilize a novel approach to target cancer cells. They promise expanded treatment options for patients. The investment signals strong confidence in Crossbow’s innovative pipeline.
Crossbow's core technology involves TCR-mimetic antibodies. These antibodies mimic T-cell receptors. This unique design allows them to target intracellular cancer proteins. Such proteins have historically proven difficult to reach. Conventional antibody therapies often fail to access these targets. Crossbow's method breaks this barrier.
The company's T-Bolt platform is central to its strategy. This platform develops a portfolio of T-cell engager therapies. T-Bolt molecules precisely bind to peptide human leukocyte antigen (pHLA) complexes on cancer cells. This mechanism directs the body’s immune system to destroy malignant cells. The platform aims to expand immunotherapy’s reach. It targets a wide spectrum of cancers, offering new hope.
A primary use of the new capital is to push CBX-250 forward. CBX-250 is Crossbow’s lead candidate. It represents a first-in-class T-cell engager. The therapy targets specific pHLA on myeloid cancer cells. This specificity is crucial for effective treatment.
CBX-250 is currently undergoing a Phase 1 clinical trial. The study is named CROSSCHECK-001. It evaluates the therapy in patients with relapsed or refractory myeloid malignancies. These severe conditions include acute myeloid leukemia. Chronic myeloid leukemia also falls within its scope. Myelodysplastic syndromes and chronic myelomonocytic leukemia are other target indications. Initial clinical data from this trial is eagerly anticipated. The company expects results by the end of 2026. This data will be critical for future development.
The financing also supports the advancement of CBX-663. This is another promising first-in-class T-cell engager. CBX-663 targets a telomerase reverse transcriptase-derived peptide HLA complex. This broadens its potential application. It represents the next wave in Crossbow’s pipeline innovation.
Crossbow Therapeutics plans to submit an Investigational New Drug (IND) application for CBX-663 soon. A Phase 1 clinical trial is slated for the third quarter of 2026. This therapy will target both hematologic and solid tumors. Its broader applicability could address a significant unmet need.
Strategic leadership changes accompany the funding. Sakae Asanuma has joined Crossbow’s board of directors. Asanuma serves as President and CEO of Taiho Ventures. Pini Orbach also joined the board. Orbach is Managing Partner of Arkin Bio Capital. Their expertise will guide Crossbow’s future direction.
Crossbow’s approach is designed to overcome limitations of current treatments. The T-Bolt platform potentially targets the entire universe of cancer proteins. This expansive capability promises to deliver impact for patients. It aims to address cancers previously considered untreatable with antibody therapies.
The company will share new insights soon. Preclinical and translational data on both CBX-250 and CBX-663 will be presented. The American Association for Cancer Research (AACR) 2026 Annual Meeting in April will host these presentations. This will offer the scientific community an early look at Crossbow’s progress.
Crossbow Therapeutics is expanding its operations. Research and development efforts will intensify. The focus remains on broadening the scope of immunotherapy. The ultimate goal is to provide next-generation TCR-mimetic immunotherapies. Patients facing limited options urgently need these innovations. This funding fuels that critical mission.
The $77 million investment underscores a shared conviction. Investors believe in the transformative potential of the T-Bolt platform. This commitment empowers Crossbow to efficiently expand its pipeline. The company aims to address cancers beyond the reach of today’s existing therapies. It represents a vital step forward in the fight against cancer.